Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-01-10

FDA Approved: ABREVA — Supplemental Application (Haleon US Holdings LLC)

View source ↗

Summary

FDA approved a supplemental application for ABREVA (docosanol) submitted by Haleon US Holdings LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABREVA (Docosanol)

Snippet

SUPPL AP for ABREVA (DOCOSANOL)